Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Triplett

Dermatology Brentwood, CA Doctor of Osteopathy

NPI 1316203649 CMS profile 4218207

2221 Balfour Rd Ste A, Brentwood, CA 94513

Open in the dashboard

General payments

$5,604

284 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Triplett of Brentwood, CA is reported in the CMS Open Payments database as having received $5,604 across 284 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $916 37
2024 General $1,121 52
2023 General $1,079 52
2022 General $1,108 61
2021 General $738 45
2020 General $507 29
2019 General $135 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Triplett
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Thomas Triplett were reported at $916. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Thomas Triplett Dermatology median Middle half National median
2019 $135 $454 $129–$1,240 $163
2020 $507 $235 $81–$756 $114
2021 $738 $377 $108–$1,108 $132
2022 $1,108 $514 $143–$1,391 $149
2023 $1,079 $607 $159–$1,674 $160
2024 $1,121 $751 $204–$1,903 $164
2025 $916 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,115 70 payments
  2. Novartis Pharmaceuticals Corporation $744 38 payments
  3. Janssen Biotech, Inc. $695 31 payments
  4. Lilly USA, LLC $457 20 payments
  5. Ortho Dermatologics, a division of Bausch Health US, LLC $362 18 payments
  6. Incyte Corporation $299 12 payments
  7. E.R. Squibb & Sons, L.L.C. $271 14 payments
  8. Pfizer Inc. $249 11 payments
  9. Regeneron Healthcare Solutions, Inc. $221 10 payments
  10. UCB, Inc. $159 9 payments
  11. Other $1,033 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,379 280 payments
  2. Education $225 4 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI $789 49 payments
  2. TREMFYA $582 24 payments
  3. COSENTYX $463 25 payments
  4. TALTZ $457 20 payments
  5. RINVOQ $293 19 payments
  6. SOTYKTU $251 13 payments
  7. SIMPONI ARIA $226 12 payments
  8. STELARA $226 12 payments
  9. SIMPONI $226 12 payments
  10. CIBINQO $215 9 payments
  11. Other $3,440 165 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

284 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record